Atorvastatin

Drug

Drug Profile

Atorvastatin is a statin lipid-lowering medicine widely used to treat dyslipidemia and reduce cardiovascular risk. It is marketed under brand names including Lipitor and is taken orally. It has been approved in the U.S. since 1996 and is available as a generic prescription drug.

Drug Class
Statin; hypolipidemic agent
Approval Status
FDA approved for medical use in the United States in 1996; prescription-only
Mechanism of Action
Inhibits HMG-CoA reductase in the liver to reduce cholesterol synthesis
Brand Names
  • Lipitor
Indications
  • Dyslipidemia
  • \Cardiovascular disease prevention\

Related News

Related Clinical Trials

NCT ID Title Status Phase
NCT07762105

Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease

NOT_YET_RECRUITING PHASE1
NCT07727681

Perioperative Statins to Prevent AFib After Lung Surgery

RECRUITING PHASE4
NCT07717788

Therapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patients

COMPLETED NA
NCT07680595

Prospective Management of Plaque Instability With Statins and Extra Folic Acid

RECRUITING PHASE1/PHASE2
NCT07668076

The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients

COMPLETED PHASE2
NCT07630363

PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC

NOT_YET_RECRUITING PHASE1/PHASE2
NCT07624604

Evaluation of the Therapeutic Efficacy of Auricular Pellets Combined With Atorvastatin 20mg in Patients With Dyslipidemia and Phlegm-Dampness Syndrome

NOT_YET_RECRUITING NA
NCT07586540

Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque

NOT_YET_RECRUITING PHASE3
NCT07568574

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

ENROLLING_BY_INVITATION NA
NCT07534592

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

ACTIVE_NOT_RECRUITING PHASE1